NGF Biology: Why Nerve Growth Factor Matters for Cognition
Nerve growth factor (NGF) was discovered by Rita Levi-Montalcini in the 1950s — work that earned her the 1986 Nobel Prize in Physiology. NGF is a neurotrophin — a class of proteins that support the survival, growth, and differentiation of neurons. Its primary receptor is TrkA (tropomyosin receptor kinase A), expressed on cholinergic neurons in the basal forebrain, sensory neurons, and sympathetic neurons.
NGF's roles relevant to cognition:
- Cholinergic neuron maintenance: Basal forebrain cholinergic neurons (BFCNs) — the primary neurons projecting to the hippocampus and cortex for memory and attention — are entirely dependent on NGF for survival and function. NGF deprivation causes BFCN atrophy; supplementation restores it. Alzheimer's disease is characterized by early loss of NGF signaling in BFCNs.
- Neuroplasticity: NGF promotes dendritic branching, axon elongation, and synaptogenesis — the structural substrate of learning and memory. TrkA signaling activates MAPK/ERK and PI3K/Akt pathways that drive these morphological changes.
- Myelination: NGF supports Schwann cell function in the peripheral nervous system, maintaining nerve conduction velocity.
- Neuroregeneration: After peripheral nerve injury, NGF gradients guide axon regrowth along the original nerve path — explaining lion's mane's traditional use for "mountain priest disease" (peripheral neuropathy) in Japanese folk medicine.
The blood-brain barrier problem: NGF protein itself cannot cross the BBB — it is too large (26 kDa). This is why intraventricular NGF infusion was explored in Alzheimer's trials but is clinically impractical. Lion's mane's small-molecule bioactives (hericenones ~400–500 Da; erinacines ~400 Da) do cross the BBB and stimulate endogenous NGF synthesis within the brain — circumventing the delivery problem.
Hericenones vs. Erinacines: Two Different Compounds, Two Different Sources
Hericenones (fruiting body only)
Hericenones A–H are aromatic compounds isolated from the fruiting body of H. erinaceus. Kawagishi's lab at Shizuoka University published the isolation and characterization of hericenones C–H in the early 1990s. Hericenones stimulate NGF synthesis in 1321N1 astrocytoma cells and primary astrocyte cultures at nanomolar concentrations. They appear to act through the NF-κB pathway and prostaglandin-mediated signaling in glial cells. Hericenones are absent from mycelium-only products.
Erinacines (mycelium only)
Erinacines A–K are cyathane diterpenoids found exclusively in the mycelium (the root-like vegetative structure). Erinacine A is the most studied — it crosses the blood-brain barrier and directly stimulates NGF synthesis in astrocytes and neurons in the CNS. Inoue et al. 2013 (Biological & Pharmaceutical Bulletin) demonstrated erinacine A penetration of the BBB in mice and dose-dependent hippocampal NGF elevation. Erinacine E shows the highest NGF-inducing potency in vitro. Erinacines are absent from fruiting-body-only products.
The practical implication: most commercial lion's mane products are either fruiting body extract (contains hericenones, lacks erinacines) or mycelium-on-grain (contains erinacines but also substantial grain starch contamination — the mycelium is grown on rice or oats and often not fully separated). Full-spectrum products combining both are the most complete but require careful sourcing verification.
Mori 2009: The Key Human RCT
Mori et al. 2009 (Phytotherapy Research) remains the most-cited clinical evidence for lion's mane cognitive effects. Design: 30 Japanese adults aged 50–80 with mild cognitive impairment (MCI), randomized to lion's mane fruiting body powder 250mg tablets (equivalent to ~750mg dried mushroom) 3 times daily (750mg extract total) or placebo for 16 weeks. Primary endpoint: MMSE (Mini-Mental State Examination) score.
Results:
- MMSE scores: +5.3 points in lion's mane group vs. −0.6 points placebo (highly significant; p<0.01)
- Improvement was progressive through the 16-week period — scores continued rising at weeks 8, 12, and 16
- Rebound after cessation: MMSE scores declined 4 weeks after stopping supplementation — suggesting the effect requires ongoing supplementation rather than producing permanent structural change
- No adverse effects in either group
Study limitations: small N (30), short duration, Japanese elderly population may not generalize, and the extract dose and standardization were not fully specified. Nevertheless, Mori 2009 remains the only double-blind placebo-controlled RCT in MCI patients and is the primary human evidence anchor for this category.
| Study | Population / Design | Extract / Dose | Finding |
|---|---|---|---|
| Mori et al. 2009 (Phytother Res) | N=30 MCI patients, 16-week double-blind RCT | Fruiting body powder 750mg/day | +5.3 MMSE points vs −0.6 placebo; progressive improvement; scores declined 4 weeks post-cessation |
| Nagano et al. 2010 (Biomed Res) | N=30 women, 4-week RCT, no cognitive impairment | Fruiting body powder 2g/day (cookies) | Reduced anxiety and depression scores vs placebo; no significant cognitive improvement in cognitively healthy subjects |
| Inoue et al. 2013 (Biol Pharm Bull) | Mice, erinacine A administration | Erinacine A oral, dose-escalation | BBB penetration confirmed by brain tissue analysis; dose-dependent hippocampal NGF elevation; neurotrophic gene upregulation |
| Li et al. 2020 (J Ethnopharmacol) | N=77 MCI patients, 49-week RCT | Lion's mane mycelium extract 3g/day | Significant improvement on cognitive assessment battery vs placebo; erinacine-containing mycelium preparation; larger and longer than Mori 2009 |
Lion's Mane Protocol and Product Selection
- Target dose: 500–1000mg standardized fruiting body extract daily, or 3g/day mycelium extract (matching Li 2020). At lower doses (250mg/day), evidence for cognitive effects is weaker. Mori 2009's 750mg/day of powder is approximately equivalent to 250–375mg concentrated extract (3:1 or 4:1 extraction ratio).
- Fruiting body vs mycelium decision: For NGF induction via hericenones (the Mori 2009 mechanism): fruiting body extract standardized to beta-glucans ≥30%. For erinacine-mediated BBB-penetrating NGF induction: mycelium extract with specified erinacine content (rare; Stamets Host Defense and a few Japanese suppliers specify this). Full-spectrum products targeting both: look for dual-extract products combining fruiting body + mycelium with both beta-glucan and erinacine standardization.
- The "mycelium on grain" problem: Many US lion's mane supplements are mycelium grown on rice or oat substrate and not fully separated. The product contains substantial grain starch (up to 50–60% of capsule content), diluting the actual mushroom bioactives. Products that test for beta-glucan content (target: ≥30%) and specify "no grain filler" are more reliably concentrated. DNA/HPLC testing from third-party labs is the gold standard.
- Timeline for effects: Cognitive effects in Mori 2009 were progressive over 16 weeks — expect 4–8 weeks minimum before assessing efficacy. NGF synthesis upregulation and neuroplastic changes require weeks to months to translate into measurable cognitive function. Patience is necessary; this is not an acute nootropic.
- Best evidence use case: MCI (mild cognitive impairment) and early cognitive decline. Evidence in cognitively healthy younger adults is much weaker (Nagano 2010 showed anxiety reduction but no cognitive score improvement in healthy women). For healthy adults, lion's mane is a long-term neuroplasticity investment rather than a short-term cognitive enhancer.
Real Mushrooms and Nammex supply fruiting-body-only extracts with third-party beta-glucan testing (≥30% beta-glucans confirmed). Host Defense (Stamets) uses mycelium and specifies erinacine content. For a full-spectrum approach, look for products from suppliers who provide a certificate of analysis showing both beta-glucan content and absence of grain contamination. Avoid any supplement listing only "polysaccharides" without beta-glucan specificity.